Tarsus Pharmaceuticals In... (TARS)
| Bid | 51.56 |
| Market Cap | 2.15B |
| Revenue (ttm) | 202.43M |
| Net Income (ttm) | -127.85M |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -16.87 |
| Forward PE | -26.42 |
| Analyst | Buy |
| Ask | 51.84 |
| Volume | 430,058 |
| Avg. Volume (20D) | 719,410.6 |
| Open | 50.58 |
| Previous Close | 50.65 |
| Day's Range | 49.55 - 52.30 |
| 52-Week Range | 20.08 - 57.28 |
| Beta | 1.06 |
About TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; a...
Analyst Forecast
According to 6 analyst ratings, the average rating for TARS stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 27.46% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call TranscriptTarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwa...
